NPS and AstraZeneca extend R&D collaboration
Under the terms of the extended agreement, the companies will continue their research collaboration for a minimum of three years, with options to extend the alliance for an
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.